Switching to Twice-Weekly Hemodialysis Can Be Done Safely
In a community-based dialysis program, nearly 10% of patients successfully converted from 3 to 2 hemodialysis sessions per week.
ERA-EDTA Congress
Semaglutide Effective in High-Risk Diabetic Kidney Disease
More than two-thirds of patients experienced a more than 5% weight loss with 12 months of etelcalcetide treatment.
Light, Moderate Alcohol Intake Linked to Lower Chronic Kidney Disease Risk
A Japanese study showed that light to moderate alcohol drinkers had a significantly decreased risk for chronic kidney disease compared with those who drank no alcohol.
Gestational Diabetes Followed by Type 2 Diabetes Ups CKD, ESKD Risk
In a study of Swedish women, gestational diabetes that progressed to type 2 diabetes was significantly associated with increased risks for chronic kidney disease and end-stage kidney disease.
Study: Etelcalcetide Can Be Used Safely in Diabetic Nephropathy
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
No Ophthalmic Effects From Roxadustat Short Term
In a study of patients on dialysis, investigators found no higher risk for retinal hemorrhages and other ophthalmic problems among roxadustat-treated patients compared with patients receiving darbepoetin alfa.
Rituximab Superior for Preventing ANCA-Associated Vasculitis Relapse
Compared with azathioprine, rituximab decreased the risk of another relapse by 70% among patients who had experienced relapse and received re-induction of remission with rituximab, a study showed.
Acute Kidney Injury Linked to Lower Kidney Stone Risk
In a propensity score matched analysis, patients with a history of acute kidney injury (AKI) had a significant 43% lower risk of kidney stones than those who never experienced AKI.
Hyperkalemia Recurrence Risk Rises Along With Number of Episodes
The risk of hyperkalemia recurrence in patients with chronic kidney disease increases for each hyperkalemia episode a person experiences.
Belimumab Plus Standard Lupus Nephritis Therapy Improves Renal Responses
Patients with LN who received belimumab in addition to standard therapy experienced a significant 49% decreased risk of renal-related events or death compared with those who received placebo plus standard therapy, a phase 3 study found.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ERA-EDTA Congress
Loading... 
Loading...